Barclays Maintains Overweight on Oruka Therapeutics, Raises Price Target to $50

Barclays analyst Etzer Darout has maintained an Overweight rating on Oruka Therapeutics (NASDAQ: ORKA) and raised the price target from $48 to $50. This adjustment reflects a positive outlook for the company's stock performance.